Table 4.

Cytokines modulated after TLR2, TLR3, TLR4, TLR7/8, and TLR9 stimulation of dNK cells.

	TLR2			TLR3			TLR4			TLR7/8			TLR9
	Med. (Range) in pg/ml		Med. of F.I (IQR)	Med. (Range) in pg/ml		Med. of F.I (IQR)	Med. (Range) in pg/ml		Med. of F.I (IQR)	Med. (Range) in pg/ml		Med. of F.I (IQR)	Med. (Range) in pg/ml		Med. of F.I (IQR)
	US	S		US	S		US	S		US	S		US	S
TNF-α	37	45	1.72#	15	37	1.68	39	47	1.38	53	92	1.32*	15	118	3.61
	(8–222)	(21–315)	(1.26–2.73)	(8–82)	(8–172)	(1.00–2.09)	(8–222)	(14–228)	(1.08–1.69)	(8–88)	(9–252)	(1.20–2.51)	(8–82)	(28–208)	3.61
IFN-γ	5823	84	1.54**	39	84	3.27**	61	138	1.61**	43	60	3.00*	44	42	1.65
	(9–1343)	(25–2032)	(1.14–1.81)	(9–65)	(18–335)	(2.12–3.55)	(9–1343)	(66–2015)	(1.32–2.52)	(9–1343)	(34–4410)	(1.35–3.42)	(9–296)	(21–529)	(0.69–1.96)
IL-6	212	608	2.10**	75	503	3.80*	102	349	2.57**	58	285	2.80**	75	279	1.97
	(39–1770)	(110–2693)	(1.50–3.16)	(13–1392)	(57–3097)	(2.48–6.59)	(30–1342)	(60–3655)	(1.79–3.81)	(14–1392)	(19–2432)	(1.74–4.90)	(14–1392)	(31–2725)	(1.79–2.69)
IL-8	13,559	28,780	1.48**	10,308	23,907	1.76**	14,192	19,867	1.32*	10,308	16,960	1.57**	12,583	31,108	2.30
	(4198–49,318)	(9668–58,981)	(1.38–1.78)	(3097–66,424)	(5439–101,964)	(1.52–2.13)	(4198–66,424)	(5525–133,561)	(1.25–1.98)	(1267–112,494)	(1992–171,431)	(1.47–1.81)	(1267–152,559)	(2799–183,374)	(1.45–2.54)
IL-1RA	376	437	1.16*	222	319	1.44*	416	396	1.19*	263	380	1.29**	276	366	1.40*
	(107–811)	(217–902)	(1.12–1.30)	(107–424)	(186–465)	(1.19–1.53)	(107–811)	(221–1117)	(1.03–1.55)	(68–811)	(107–831)	(1.19–1.46)	(68–424)	(148–465)	(1.14–2.03)
IL-2RA	128	217	1.39*	248	464	1.66**	200	354	1.04	192	286	1.34**	109	298	2.23*
	(44–603)	(97–832)	(1.28–1.99)	(32–657)	(32–910)	(1.29–1.96)	(32–603)	(32–723)	(1.00–1.42)	(72–657)	(117–886)	(1.23–1.59)	(44–657)	(97–804)	(2.20–2.90)
MIP-1α	727	1525	1.66**	987	2094	2.12**	1115	1647	1.27*	845	1416	(248–12,185)	1.80**	605	1411
	(106–6489)	(367–9796)	(1.45–2.08)	(129–3329)	(291–20,723)	(2.04–2.26)	(106–3553)	(462–4377)	(1.04–1.98)	(128–6489)	(248-12,185)	(248–12,185)	(1.28–2.21)	(129–3068)	(523–3380)
MIP-1β	3477	3895	1.33**	2021	3431	1.36**	4472	4705	1.23**	2422	3774	1.30**	1800	2882	1.74
	(258–7984)	(1850–10,685)	(1.15–1.38)	(341–6092)	(604–7841)	(1.25–1.76)	(341–10,820)	(725–19,665)	(1.07–1.86)	(258–7984)	(418–13,031)	(1.20–1.62)	(258–5829)	(1895–4916)	(1.41–2.08)
RANTES	187	267	1.21**	291	420	1.41*	285	342	1.28*	373	493	1.27**	266	262	1.02
	(17–1576)	(83–2353)	(1.10–1.58)	(26–1576)	(45–1877)	(1.28–1.77)	(26–1576)	(120–2216)	(1.02–2.07)	(26–2906)	(40–3043)	(1.18–1.52)	(17–678)	(61–424)	(0.70–1.40)
MCP-1	787	748	1.19*	226	591	2.43	297	750	1.31*	203	594	1.61**	226	447	2.23*
	(187–3088)	(250–3525)	(1.10–1.29)	(37–11,388)	(97–16,104)	(1.34–4.09)	(37–4004)	(57–4497)	(1.11–1.75)	(64–8118)	(259–12,139)	(1.42–3.98)	(64–11,389)	(304–21,969)	(1.79–4.19)
GM-CSF	175	298	1.49*	134	226	2.14*	278	292	1.40*	177	292	1.89*	108	307	2.86*
	(34–3124)	(107–4250)	(1.25–2.54)	(25–741)	(74–1310)	(1.73–4.03)	(34–3124)	(117–4416)	(1.13–1.90)	(11–3124)	(67–4439)	(1.53–1.96)	(25–528)	(90–989)	(2.33–3.46)

Med., Median; F.I, fold increase; IQR, interquartile range; US, unstimulated; S, stimulated.

^*p < 0.05;

^**p < 0.01.

^#Lowest probability that can be reached.